The Heat Map shows these symbols by color. Each symbol can be clicked to scroll to the symbol details.
Below is a clickable Heat Map of the 1 symbols on this page. The percent change is based on Monday's prices. Each symbol is a hyperlink or shortcut to more information.BIIB 2.59%
Market Cap 51 Billion
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
EPS 8.40 P/E Ratio 10.77
Previous Tue, Jul 23, 2019
Latest Tue, Oct 22, 2019 (27 days ago) Price +26.29%
Pay Date --
Sep 4, 2019
Jan 23, 2019
|Symbol||Price||Day Δ||YTD Δ|
How can we make Symbol Surfing better?
©2019 Symbol Surfing All Rights Reserved.
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.